Evacetrapib, also known as LY2484595, is a CETP inhibitor currently under development by Eli Lilly & Company. LY2484595 inhibits cholesterylester transfer protein, which transfers and thereby increases high-density lipoprotein and lowers low-density lipoprotein. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure, which led to excess cardiac events when it was studied. Evacetrapib does not have the same effect. When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile. (Source: http://en.wikipedia.org/wiki/Evacetrapib). (1S,4r)-4-(((S)-5-((3,5-双(三氟甲基)苄基l)(2-甲基-2H-四氮唑-5-基)氨基)-7,9-二甲基-2,3,4,5-四氢-1H-苯并[b]氮杂卓-1-基)甲基)环己烷甲酸
CAS 1186486-62-3 MFCD286486623
化学结构图
SMILES: Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1
化学属性
| Mol. Weight | 638.65 |
|---|---|
| Appearance | white solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name Translation | (1S,4r)-4-(((S)-5-((3,5-双(三氟甲基)苄基l)(2-甲基-2H-四氮唑-5-基)氨基)-7,9-二甲基-2,3,4,5-四氢-1H-苯并[b]氮杂卓-1-基)甲基)环己烷甲酸 |
|---|---|
| Chemical Name | Evacetrapib, also known as LY2484595, is a CETP inhibitor currently under development by Eli Lilly & Company. LY2484595 inhibits cholesterylester transfer protein, which transfers and thereby increases high-density lipoprotein and lowers low-density lipoprotein. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure, which led to excess cardiac events when it was studied. Evacetrapib does not have the same effect. When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile. (Source: http://en.wikipedia.org/wiki/Evacetrapib). |
| Formula | C31H36F6N6O2 |
| Synonym | LY2484595; LY 2484595; LY-2484595; Evacetrapib. |
| IUPAC Name | (1S,4r)-4-(((S)-5-((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)methyl)cyclohexanecarboxylic acid |
| InChIKey | IHIUGIVXARLYHP-YBXDKENTSA-N |
| InChI | InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20-,22-,26-/m0/s1 |
| Canonical SMILES | O=C([C@H]1CC[C@H](CN2C3=C(C)C=C(C)C=C3[C@@H](N(CC4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)C5=NN(C)N=N5)CCC2)CC1)O |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- Evacetrapib, also known as LY2484595, is a CETP inhibitor currently under development by Eli Lilly & Company. LY2484595 inhibits cholesterylester transfer protein, which transfers and thereby increases high-density lipoprotein and lowers low-density lipoprotein. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure, which led to excess cardiac events when it was studied. Evacetrapib does not have the same effect. When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile. (Source: http://en.wikipedia.org/wiki/Evacetrapib).
相关文献及参考
- [1]. Cao G, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011 Dec;52(12):2169-76.
